Author Summary
CD44 and TNFSF14 Identified as Key Immune Targets in Glioblastoma
New Insights into Glioblastoma’s Immune Evasion: CD44 and TNFSF14 Take Center Stage Glioblastoma (GBM) remains one of the most aggressive and lethal cancers, with a median survival of just 15 months. Despite intensive treatment that […]